The SBC Medical Group Holdings Incorporated (Nasdaq: SBC) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed issuer with associated redeemable warrants trading under the symbol SBCWW, SBC submits a range of filings that document its financial condition, material events, and capital markets activity.
Among the most relevant documents for investors are current reports on Form 8-K, which SBC uses to announce material events such as quarterly financial results, tender offers and acquisitions, index inclusions, and capital strategy updates. For example, the company has filed 8-K reports to furnish press releases on quarterly results, to describe its inclusion in the Russell 3000 Index, and to summarize a tender offer for shares of Waqoo, Inc., a regenerative medicine research and development company. These filings provide detail on SBC’s operating performance, investment activities, and strategic direction.
Investors can also review filings related to capital structure and financing, including registration statements such as the company’s shelf registration on Form S-3. That registration statement, referenced in SBC’s news releases and 8-K filings, enables the company to offer and sell specified amounts of common and preferred stock in future offerings and also covers securities associated with its prior business combination transaction.
On Stock Titan, SBC’s filings are complemented by AI-powered summaries designed to help readers interpret complex regulatory documents. These summaries highlight key points from lengthy filings, such as the nature of material events disclosed in Form 8-K, the scope of registered securities in shelf filings, and the implications of tender offers or strategic investments. The page updates as new SBC filings are posted to the SEC’s EDGAR system, giving users a centralized view of the company’s regulatory history and ongoing disclosure record.
SBC Medical Group Holdings Incorporated (SBC) reported two cybersecurity incidents in Japan on November 16, 2026. In a database managed by its Japanese subsidiary, an unauthorized third party accessed and extracted customer information. The basic-information category covered 1,624,000 individuals; listed categories also included reservation-request information for 255,416 individuals and website inquiries for 217,769. Employee account information involved approximately 20,000 records, and employment information including bank and pension details was affected for 459 employees. The method and full scope remain under investigation.
A separate incident involved clinic administrator accounts on Tribeau, a third-party reservation service used by 56 clinics; accessed information included reservation-only information for 12,641 individuals and treatment information for 6,804. SBC isolated the affected server, blocked access, invalidated clinic passwords on Tribeau and reported the database incident to Japan’s Personal Information Protection Commission; it decided to commission an external investigation. It has not confirmed unauthorized acquisition of electronic medical records or secondary misuse. The financial impact remains unestimated: response costs are expected, and relevant medical corporations suspended television and certain other advertising for a limited period, which may reduce new patient inquiries. A portion of response costs may be covered by cyber insurance, subject to policy terms and limits.
SBC Medical Group Holdings Incorporated (SBC) reported third-quarter 2026 revenue of $58.6 million, versus $43.4 million a year earlier, and net income attributable to SBC of $15.7 million, versus $12.8 million. For the nine months ended September 30, 2026, revenue was $150.8 million versus $134.0 million, while attributable net income was $37.7 million versus $36.8 million. Related-party revenue was $53.5 million for the quarter and $135.2 million for the nine-month period.
SBC generated $50.2 million in operating cash in the first nine months of 2026, compared with using $27.3 million in the same 2025 period. Cash and equivalents were $198.4 million as of September 30, 2026, and bank and other borrowings were $33.6 million, versus $42.8 million as of December 31, 2025. SBC deconsolidated AMM on June 10, 2026, after its CEO and controlling shareholder repaid $5.2 million AMM owed to an SBC subsidiary; SBC reported no continuing involvement, financial-support obligations or loss exposure related to AMM. Following Waqoo’s acquisition and consolidation, SBC reported two segments: SBC core and Waqoo.
SBC Medical Group Holdings Inc. reported third-quarter 2026 revenue of $58.6 million, up 35% year over year. Income from operations was $26.4 million, up 66%, and net income attributable to SBC Medical was $15.7 million, up 22%. Adjusted EBITDA, a non-GAAP measure, was $27.6 million, up 66%; its margin was 47%, compared with 38% a year earlier. Net income margin was 27%, down 3 percentage points, and basic EPS was $0.15, up 25%.
Higher management services revenue, service-fee revisions announced in August, and Waqoo consolidation contributed to revenue growth. At September 30, 2026, SBC Medical's support and partnership network included 293 clinic locations, 36 more than a year earlier. Trailing-12-month patient visits were 7.06 million, up 9%, while average spend per visit was $290, up 4%.
For the first nine months of 2026, operating cash flow was $50.2 million, compared with $27.3 million used in the prior-year period. At September 30, 2026, cash and cash equivalents were $198 million, and Net Cash, a non-GAAP measure, was $154 million. The company said it is developing proprietary local large language model infrastructure and a DNA methylation-based test to estimate biological age, and advancing clinic operating systems through its capital and business alliance with Atomic Software.
SBC Medical Group Holdings Incorporated reported solid results for the quarter ended June 30, 2026. Total revenues were $49.19 million, up from $43.36 million a year earlier, driven mainly by related-party revenues. Quarterly income from operations rose to $18.96 million from $14.55 million, and net income attributable to the company increased to $10.69 million from $2.46 million, with basic and diluted EPS of $0.10.
For the first six months of 2026, total revenues were $92.25 million versus $90.69 million in 2025, while net income attributable to the company was $22.00 million compared with $23.96 million. Operating cash flow improved markedly, moving from a use of $6.41 million in the prior-year period to positive cash provided of $31.74 million. Cash and cash equivalents increased to $184.31 million as of June 30, 2026, against total bank and other borrowings of $37.75 million, supporting a total asset base of $406.66 million and stockholders’ equity of $279.92 million.
The company recorded a $0.57 million loss from its equity method investment in OT Midco and a significant foreign currency translation loss of $9.57 million, which reduced accumulated other comprehensive income. During the quarter, SBC deconsolidated its variable interest entity AMM; the CEO’s repayment of AMM’s obligations generated a $3.65 million deemed capital contribution, boosting additional paid-in capital. Management also introduced two reportable segments (SBC core and Waqoo) and continues to highlight heavy reliance on a small number of major customers.
SBC Medical Group Holdings reported strong results for the quarter ended June 30, 2026. Total revenues were $49 million, up 13% year-over-year, while net income attributable to SBC Medical rose to $11 million, a 335% increase. Net income margin improved to 22%, and Adjusted EBITDA reached $20 million, up 32%, with a 41% Adjusted EBITDA margin. Basic EPS was $0.10, up 400% year-over-year.
Management attributes the reacceleration to fee expansion in its points business, AI-enabled service enhancements, and steady growth in supported medical corporations. As of June 2026, SBC supported 287 locations, 34 more year-over-year, with last-twelve-month patient visits of 6.9 million, up 10%, and average spend per visit of $287, up 9%.
For the first half of 2026, revenues were $92 million versus $91 million a year earlier, while net income attributable to SBC Medical was $22 million versus $24 million. Adjusted EBITDA was $38 million, slightly below $40 million in the prior-year period. Cash and cash equivalents increased to $184.3 million, supported by $31.7 million in net cash provided by operating activities.
SBC Medical Group Holdings Incorporated reported that, following director Mike Sayama’s decision not to stand for re‑election at the July 8, 2026 annual meeting, its board and Audit Committee no longer meet Nasdaq independence requirements under Listing Rule 5605. Nasdaq notified the company of this non‑compliance but granted a cure period until the earlier of the next annual shareholders’ meeting or July 9, 2027, or, if that meeting occurs before January 5, 2027, until January 5, 2027. The board now has four members, two of whom are independent, and the Audit Committee has two independent members. The company is actively seeking a fifth independent director to restore compliance and fill committee roles.
Stockholders approved a Restated Charter, including changes to move from plurality to majority voting for directors, remove the “for cause only” removal limitation, opt out of Section 203 of the DGCL, add officer exculpation, and make technical updates. They also approved amended and restated bylaws that modernize quorum rules, tighten advance notice and disclosure standards for director nominations and other business, incorporate universal proxy requirements, require resignation offers from directors who fail to receive a majority vote in uncontested elections, and refine procedures for stockholder meetings. All seven proposals on the agenda, including four director elections and ratification of MaloneBailey, LLP as auditor for 2026, received strong shareholder support, with a quorum of 93,987,291 shares present out of 102,576,943 outstanding and entitled to vote.
SBC Medical Group Holdings Incorporated is calling a fully virtual 2026 annual stockholder meeting on July 8, 2026 (ET) / July 9, 2026 (JST) to elect four directors and vote on several governance changes. Stockholders of record at the close of business on May 20, 2026, when 102,576,943 common shares were outstanding and entitled to vote, may participate online via control number.
Proposals include electing directors for one-year terms, ratifying MaloneBailey, LLP as auditor for 2026, and multiple amendments to the Current Charter. These charter changes would eliminate plurality voting for directors, remove the “for cause only” director removal standard, opt out of Section 203 of the Delaware General Corporation Law, provide for officer exculpation, and make technical updates. The board recommends voting FOR all nominees and FOR each proposal.
The company describes its board structure, committee responsibilities, related-party review process, executive and director compensation, and notes it is a Nasdaq “controlled company,” with CEO Dr. Yoshiyuki Aikawa controlling approximately 81.7% of the voting power.
SBC Medical Group Holdings Incorporated announced that independent director Mike Sayama informed the company on May 14, 2026 that he will not seek re-election at the forthcoming 2026 Annual Meeting of Stockholders. The board will reduce its size to four members immediately before the meeting.
The board is conducting a search for a new independent director and plans to expand back to five members once a suitable candidate is identified. The new director is expected to join the nominating and corporate governance, compensation, and audit committees, filling roles currently held by Mr. Sayama. His decision is stated as not stemming from any disagreement with the company, management, or the board.
On behalf of SBC Medical Group Holdings Incorporated, the board is soliciting proxies for the 2026 annual meeting to be held virtually at 9:00 a.m. JST on July 9, 2026 (8:00 p.m. ET on July 8, 2026). Four directors will be elected, MaloneBailey, LLP is proposed for ratification as independent auditor for fiscal year ending December 31, 2026, and stockholders are asked to approve multiple charter amendments, including elimination of plurality voting, removal-for-cause limitation, opting out of Section 203 of the DGCL, officer exculpation, and other technical changes.
The record date for voting is May 20, 2026; there were 102,576,943 shares outstanding as of that date (after deducting 270,000 shares held by a wholly-owned subsidiary). The board recommends a FOR vote on all proposals.